[Editor’s Note: We’re sharing this edition of Private Briefing with you because the two profit-doublers Bill is looking at right now are about to break out, thanks to a little-understood catalyst that heralds big share price hikes. Here’s Bill…]
When I earned my MBA from the Rochester Institute of Technology back in the mid-1990s, my focus was finance and investing.
But it was a management professor who clued me in to some of the best ways to "look past the numbers" and understand what really makes a big company tick.
The professor, Janet C. Barnard, retired a few years back and, sadly, passed away in 2012.
The talks that she and I had were invigorating "mini-lessons" - which is why we were still having them years after I tacked my graduate-degree diploma to my office wall.
I often "shared" those lessons with my readers - quoting the management professor in stories I wrote back during my days at The Baltimore Sun, as well as in columns I've written for you folks here at Money Map Press.Now those lessons will pay off again as we look at these huge biotech opportunities...